Senzo Receives Funding from the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test
News
Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022
Superior to Meropenem for the Primary Efficacy Endpoint
Safety Profile Consistent with Meropenem
Treventis Awarded $2.97M Grant from the U.S. Department of Defense
Funds for Development of Its Anti-Tau Drug Against Neurodegenerative Diseases
Wellsheet Introduces EHR Workflow Relief to Increase Efficiency During Critical Nursing Shortage
Virtual Nursing Station with Real-Time Notifications Increases Care Team Collaboration and Patient Care Quality
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer’s Disease
Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer’s Disease
Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract
Total award of up to $318M for development and procurement of novel antibiotic cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections
Relmada Therapeutics Announces Completion of Treatment in Company’s Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder